Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-paclitaxel, Apatinib, and Camrelizumab in Advanced Gastric Cancer
NCT04286711Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Mar 2020
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib, nab-paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by China Medical University. Status: unknown.
02
Drugs
camrelizumabRivoceranibnab-paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04286711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286711.